The Institute for Clinical and Economic Review (ICER) has issued a report recommending that dupilumab (Dupixent) offers good long-term value and important clinical benefit for patients with moderate-to-severe atopic dermatitis.
The Institute for Clinical and Economic Review (ICER) has issued a report recommending that dupilumab (Dupixent), Regeneron/Sanofi’s recently approved biologic medication, offers good long-term value and important clinical benefit for patients with moderate-to-severe atopic dermatitis and should be financially accessible to patients.
The report notes that atopic dermatitis, a common occurrence in children, can be a burden for patients and their families. The disease can have a significant impact on a person’s quality of life and its aesthetic impact can lead to social stress and isolation. Existing treatments for atopic dermatitis have well-known adverse events and may be of limited use for chronic disease, the report notes. In clinical trials for dupilumab for moderate-to-severe atopic dermatitis the report concluded that consistently across all trials, dupilumab met prespecified targets representing successful outcomes in 30% to 44% of patients, compared with 2% to 12% for placebo. Results were similar with weekly or every-other-week dosing, and in patients treated or not with topical corticosteroids.
ICER issued the report and summary of a May 2017 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), a nationally recognized community forum that convenes 3 times per year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of healthcare. ICER’s report also assessed the comparative clinical effectiveness of crisaborole (Pfizer’s Eucrisa, approved in December 2016) for mild-to-moderate disease. Insight into the patient experience was provided by the National Eczema Association.
During the public meeting, the Midwest CEPAC voted that the evidence was insufficient to assess the net health benefit of crisaborole compared with topical corticosteroid and topical calcineurin inhibitors. The Council voted that the evidence shows dupilumab to be superior to treatment with nonpharmacologic interventions or with cyclosporine for adults with moderate-to-severe atopic dermatitis for whom topical therapies have not been effective. Further, the Council found dupilumab to provide intermediate value for patients with moderate disease, and for a mixed population of patients with moderate-to-severe disease. For patients with severe disease, the Council voted that dupilumab is a high-value treatment.
The following key policy recommendations was the result of a roundtable discussion among experts, including payers, patients with atopic dermatitis, and a representative of a drug manufacturer:
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.